Monitoring and treatment after stem cell transplant for myelodysplastic syndrome
Tests treatment guided by residual disease markers in adults with myelodysplastic syndrome after transplant.
Plain-language title generated from the registry record
Registry title: NMDSG-14B2
Key facts
- Where
- Aarhus N and Copenhagen Oe, DenmarkSee the 2 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with myelodysplastic syndrome (MDS) who can have a stem cell transplant. It tests treatment after transplant, guided by traces of leftover disease.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Myelodysplastic syndrome (MDS), mixed myelodysplastic/myeloproliferative syndrome, or acute myeloid leukemia (AML) with myelodysplasia related dysplasia and 20-29% marrow blasts.
- Biomarker or test result
- A traceable genetic change must have been found, either in the screening sequencing panel or in the one done at diagnosis.
Main reasons for not taking part
- No traceable genetic change found
- Uncontrolled high blood pressure
- Uncontrolled heart, liver, kidney or other medical or psychiatric disorders
- Mental inability, reluctance or language difficulties that make it hard to understand taking part
Read by machine on 9 November 2026.
Where in Denmark
- Aarhus University HospitalAarhus N, DenmarkTaking people
- RigshospitaletCopenhagen Oe, DenmarkTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorTrial details
- Who runs it
- Karolinska University Hospital
- Trial code
- EU 2024-511651-17-00
- Record updated
- 27 May 2026
- Original description
To prevent clinical events (relapse or non-relapse death) in minimal residual disease (MRD) positive subjectsRead full original descriptionShow less
A phase II multicenter single-armed study using subject-specific minimal residual minimal disease markers to adopt treatment after allogeneic stem cell transplantation for subjects with myleodysplastic syndrome - MDS
To prevent clinical events (relapse or non-relapse death) in minimal residual disease (MRD) positive subjects
Inclusion: Signed informed consent; Age ≥ 18 years; Subjects eligible for stem cell transplantation; Subjects having the disease myelodysplastic syndrome (MDS), mixed myelodysplastic/myeloproliferative syndrome or acute myeloid leukemia (AML) with myelodysplasia related dysplasia and 20-29% marrow blasts; All female subjects of childbearing potential have to have negative pregnancy test within 2 weeks prior to inclusion to the study.
Exclusion: Uncontrolled hypertension, heart, liver, kidney related or other uncontrolled medical or psychiatric disorders; No traceable genetic aberration identified either in screening next generation sequencing panel or next generation sequencing panel performed at diagnosis; Mental inability, reluctance or language difficulties that results in difficulty understanding the meaning of study participation.